Bank of America Corp DE Boosts Holdings in Viking Therapeutics Inc (VKTX)

Bank of America Corp DE boosted its position in shares of Viking Therapeutics Inc (NASDAQ:VKTX) by 2,349.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 252,609 shares of the biotechnology company’s stock after buying an additional 242,296 shares during the quarter. Bank of America Corp DE’s holdings in Viking Therapeutics were worth $1,932,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Fiera Capital Corp bought a new stake in shares of Viking Therapeutics during the 4th quarter valued at $11,167,000. BlackRock Inc. raised its position in shares of Viking Therapeutics by 22.4% during the 4th quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock valued at $31,361,000 after acquiring an additional 749,505 shares during the last quarter. Vanguard Group Inc raised its position in shares of Viking Therapeutics by 21.4% during the 3rd quarter. Vanguard Group Inc now owns 2,877,287 shares of the biotechnology company’s stock valued at $50,123,000 after acquiring an additional 508,097 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Viking Therapeutics by 21.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,877,287 shares of the biotechnology company’s stock valued at $50,123,000 after acquiring an additional 508,097 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of Viking Therapeutics during the 4th quarter valued at $2,981,000. 65.13% of the stock is currently owned by hedge funds and other institutional investors.

VKTX opened at $8.46 on Monday. Viking Therapeutics Inc has a 12 month low of $4.05 and a 12 month high of $24.00. The firm has a market capitalization of $609.36 million, a P/E ratio of -21.15 and a beta of 2.56.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.02. On average, research analysts expect that Viking Therapeutics Inc will post -0.45 earnings per share for the current year.

Several analysts have commented on VKTX shares. BidaskClub cut shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, March 6th. Maxim Group dropped their target price on shares of Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 14th. Leerink Swann started coverage on shares of Viking Therapeutics in a research report on Friday, February 22nd. They set a “market perform” rating and a $10.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a research report on Friday, March 29th. Finally, Svb Leerink started coverage on shares of Viking Therapeutics in a research report on Friday, February 22nd. They set a “mkt perform” rating for the company. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $22.54.

TRADEMARK VIOLATION NOTICE: “Bank of America Corp DE Boosts Holdings in Viking Therapeutics Inc (VKTX)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.com-unik.info/2019/05/06/bank-of-america-corp-de-boosts-holdings-in-viking-therapeutics-inc-vktx.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Featured Article: Depreciation

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics Inc (NASDAQ:VKTX).

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit